NobleCon15 Agenda

Sunday, January 27, 2019

5:00pm – 7:00pm; W Fort Lauderdale Conference Level 2nd Level

NobleCon EARLY check-in
Get your name badge and schedule Sunday evening and avoid the early morning rush. Wine, beer and soft drinks served.

Monday, January 28, 2019 - DAY ONE NobleCon15 - W Fort Lauderdale Conference Level 2nd Level

7:15am - NobleCon15 Check-in Opens
7:30am - Continental Breakfast Served

8:00am - Keynote Address - Great ROOM 1 & 2

Research coverage for SmallCaps is shrinking. Liquidity is drying. The valuation spread between the S&P and Russell is at its widest. BUT, the microcap equity universe REMAINS ripe with innovation and valuable products and services that fuel our economy. Clearly, there’s a disconnect. We see it, companies see it, and investors who recognize that inefficiency means opportunity are watching closely. What doesn’t Washington see? Our panel of SmallCap experts will be dissecting the flaws and opportunities of the current state of the SmallCap equity universe.

As part of Noble’s pilot media series, IPO, we look at the Ideas, People, and Opportunities that drive value in the world of emerging growth. We couldn’t be more excited to announce our distinguished panel of experts to launch this event, and whom, collectively, have experienced these issues from every angle – as institutional investors, CEOs, and Washington policymakers:

David Weild is Founder, Chairman and CEO of Weild & Co. The studies that he co-authored have documented the long-term decline in equity capital formation in the United States and provided the core arguments that gave rise to the JOBS Act and many of the specific provisions contained in the JOBS Act. For these reasons, he has been called “The father of the JOBS Act.” David has also called for a “JOBS Act 2” or “JOBS Act Part 2” - language increasingly heard on Capitol Hill. The work has been cited by a broad range of legislators, regulators, academics, the IPO Task Force and the White House Jobs Council leading up to the JOBS Act. David has testified in Congress (most recently in June 2013) and at the SEC (most recently at the Roundtable on Decimalization) on these and other market issues and attended the signing of the JOBS Act by President Obama in the Rose Garden on April 5, 2012. David is a former Vice Chairman and executive committee member of The NASDAQ Stock Market and spent years running Wall Street investment banking and equity capital markets businesses. David holds an MBA from the Stern School of Business and a BA from Wesleyan University. He studied on exchange at The Sorbonne, Ecole des Haute Etudes Commerciales and The Stockholm School of Economics. He is also Chairman of the Board of Tuesday’s Children, the 9/11 charity.

Josh Scheinfeld has over 20 years experience investing in public and private companies and since 1999 has been a founder of investment funds that have funded or committed to fund over $2.0 billion. In addition, Mr. Scheinfeld is a serial entrepreneur and has extensive experience in starting, running and raising capital for public and private companies as well as real estate ventures. While a management consultant at McKinsey & Company, Inc., he was part of teams that solved business problems for Fortune 500 companies. Mr. Scheinfeld practiced law at the Chicago law firm of Katten Muchin Rosenman LLP where he specialized in corporate acquisition, securities and venture capital transactions. Mr. Scheinfeld received his Juris Doctor, Cum Laude, from Harvard Law School. Mr. Scheinfeld graduated Phi Beta Kappa with a BA in Economics and Distinction in all Subjects from Cornell University.

Colin Goddard, PhD, is Chairman and CEO of BlinkBio – an innovative biotechnology company developing cancer therapeutics. Dr. Goddard was formerly CEO of OSI Pharmaceuticals for 12 years, raising over $1.5 billion and overseeing the development, launch and commercialization of the lung cancer drug Tarceva through to OSI’s $4 billion acquisition by Astellas. He also Chairs the board of Mission Therapeutics and is was board member of the drug conjugate company Endocyte (NASDAQ:ECYT), which was bought by Novartis in December 2018 for $2.1B. Dr. Goddard obtained his PhD in cancer chemotherapy in the UK and completed post-doctoral training at the National Cancer Institute in Bethesda, MD.


Brant Pinvidic is an award winning film director, veteran television producer, and the founder and CEO of INvelop Entertainment. In 2015, he produced and directed his first feature documentary, entitled Why I’m Not on Facebook. The critically acclaimed film was an award winner at the Manhattan Film Festival, is airing in more than 50 countries around the world, and available on iTunes and Amazon Prime. Brant is an accomplished public speaker and sales and presentation coach to CEO’s across the country. Widely regarded as one of the great creative sellers in the television industry, his straightforward approach and “3 Minute Rule” have helped make Brant one of the top C-level consultants in the business. He currently hosts a weekly podcast that has featured guests, such as Tony Robbins, Robe Lowe, Dennis Kucinich, and many others.

9:30am - Corporate Presentations Begin - Studios 2 3 & 4 (studio 1 from 10:00am) - Four simultaneous tracks, 25 minute intervals with a five minute break between sessions

Detailed on personalized schedules, printed schedules, on video displays at each room and main reader board

10:30am - One-on-one Scheduled Meetings Begin - Great Room 1 & 2; Studio 5 - 25 minute intervals with a five minute break between sessions

Meetings are pre-arranged prior to the opening of NobleCon and detailed on personalized schedules.

11:45am - 1:00pm - Lunch Available – seating only available in presentation rooms

5:00pm - Last round of corporate presentations and scheduled meetings begin - Great Rooms 1 & 2; Studios 1-5 – Ends at 5:25pm

5:30pm - PANEL PRESENTATION - Studio 1 - Researching the Cause of Alzheimer’s Disease – Quest for a Cure


  • Chairperson: Josée Leysen, Ph.D., Noble Capital Markets Scientific Advisory Board
  • James Kupiec, MD, Chief Medical Officer, ProMIS Neurosciences, Inc. (TSX:PMN)
  • Kenneth Moch Chief Executive Officer, Cognition Therapeutics (Private)
  • Sietske Sikkes, Ph.D., Alzheimer’s Center, University Medical Center Amsterdam & Massachusetts General Hospital, Department of Neurology, Harvard Aging Brain Study
  • Ralph Kern, MD, MHSc, Chief Medical Officer & Chief Operating Officer, BrainStorm Cell Therapeutics (Private)
  • Martin Tolar, MD, Ph.D., Founder, President & Chief Executive Officer, Alzheon, Inc. (Private)

5:30pm - PANEL PRESENTATION - Studio 3 - Novel Therapies at the Cutting Edge of Cancer Research


  • Chairman/Moderator - Dr. James Mulé, Director, Moffitt Cancer Center, Noble’s S.A.B Member
  • Mark Erlander, PhD, Chief Executive Officer, Trovagene, Inc. (NasdaqCM:TROV)
  • Julien Pham, MD, MPH President and Chief Operating Officer, Genprex, Inc. (NasdaqCM:GNPX)
  • Colin Goddard, MD, MPH, Chief Operating Officer and Founder, BlinkBio (Private)
  • Douglas Calder, President, Vycellix (Private)
  • Brian Schwartz, MD, Chief Medical Officer, ArQule, Inc. (NasdaqGM:ARQL)
  • Dr. Steven J. Evans, Chief Executive Officer, Oncolyze, Inc. (Private)

5:30pm - PANEL PRESENTATION - Studio 4 - Voices of Experience: Marketing Early-Stage Natural Resource Companies to Investors


  • Dr. Keith Barron, Chairman and Chief Executive Officer, Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (FSE: 20Q)
  • Mr. Gregory Crowe, President, Chief Executive Officer and Director, Silver One Resources Inc. (TSXV: SVE) (OTC Pink: SLVRF) (FSE: BRK1)
  • Mr. Henk van Alphen, Chief Executive Officer and Director, Wealth Minerals Ltd. (TSXV : WML) (OTCQX: WMLLF) (SSE: WMLCL) (FSE: EJZN)
  • Mr. John Brda, President and Chief Executive Officer, Torchlight Energy Resources, Inc. (NASDAQ: TRCH)
  • Mr. Douglas Bartole, President and CEO, InPlay Oil Corp. (TSXV: IPO)

7:30pm – “The After” - Great Rooms 1 & 2; Conference Pre-function area - The Ultimate Adventure in Networking – **NOTE: wear the shirt you were given at check-in and wear your name badge / lanyard**

Tuesday, January 29, 2019 - DAY TWO NobleCon15 - W Fort Lauderdale Conference Level 2nd Level

7:30am - NobleCon15 Check-in Opens
7:45am - Continental Breakfast Served

8:30am - PANEL PRESENTATION - Studio 1 - Diabetes: Is a cure for the disease closer than we think?


  • Camillo Ricordi, MD, Director, Diabetes Research Institute, Noble S.A.B. Member
  • Steve Perrin, PhD, Chief Executive Officer and Founder, Anelixis Therapeutics, LLC (Private)
  • William L. Rust, PhD, Chief Executive Officer and Founder, Seraxis, Pte. Ltd. (Private)
  • Michael Fox, MS, RDN, LN, Michael Fox, DugalHealth L.L.C. (Private)
  • Michael G. Wright, President & CEO, Inolife Sciences (Private)
  • Philip Toleikis, PhD, President and Chief Executive Officer, Sernova Corp. (TSXV:SVA)
  • Steve Glover, Chief Executive Officer, Chairman, and Co-Founder, Variant Pharmaceuticals, Inc. (Private)
  • Michael Castagna, PharmD, MannKind Corporation (NasdaqGM:MNKD)

8:30am - PANEL PRESENTATION - Studio 3 - Treatment Advances in Age-related Macular Degeneration and Diabetic Macular Edema


  • Joseph Gardner, PhD, President and Founder, Aerpio Pharmaceuticals, Inc. (NasdaqCM:ARPO)
  • Richard S. Eiswirth, President and Chief Executive Officer, Alimera Sciences, Inc. (NasdaqGM:ALIM)
  • Brian Culley, Chief Executive Officer, Biotime, Inc. (AMEX:BTX)
  • David Rand, MD, Rand Eye Institute
  • William Rand , MD, Rand Eye Institute

8:30am - PANEL PRESENTATION - Studio 4 - Navigating the Next Market Uptrend in Maritime Transportation: showcasing the best opportunities in the space


  • John Wobensmith, Chief Executive Officer, Genco Shipping & Trading Limited (NYSE:GNK)
  • Gary Vogel, Chief Executive Officer, Eagle Bulk Shipping Inc. (NASDAQ:EGLE)
  • Stamatis Tsantanis, Chief Executive Officer, Seanergy Maritime Holdings Corp. (NASDAQ:SHIP)
  • Jeff Pribor, Chief Financial Officer, International Seaways, Inc. (NYSE:INSW)
  • Eddie Valentis, Chief Executive Officer, Pyxis Tankers Inc. (NASDAQ:PXS)

09:30am - Corporate Presentations Begin - Studios 1, 2, 3 & 4 - Four simultaneous tracks, 25 minute intervals with a five minute break between sessions

Detailed on personalized schedules, printed schedules, on video displays at each room and main reader board

09:30am - One-on-one Scheduled Meetings Begin - Great Room 1 & 2; Studio 5 - 25 minute intervals with a five minute break between sessions

11:30am - 12:45pm - Lunch Available – seating only available in presentation rooms

3:00pm - PANEL PRESENTATION - Studio 3 - Cannabiz- Is it all smoke and mirrors or do opportunities abound?


  • Chair: Michael Richard Farley, PhD, Director, Valor Management SA
  • Ken Tapp, Chief Executive Officer, Chief Technology Officer, and Chairman. MjLink
  • Perry Antleman, Chief Executive Officer, CBDMEDIC (Private)
  • Avtar Dhillon, Executive Chairman and President, Emerald Health Therapeutics, Inc. (TSXV:EMH)
  • Brian Murphy, MD,MPH, MBA, Chief Executive Officer, Chief Medical Officer, and Board Member, Nemus Biosciences, Inc. (OTCPK:NMUS)
  • Larry Feigen, Chairman and Chief Executive Officer, Yes Investments LLC

4:00pm - Last round of corporate presentations and scheduled meetings begin - Great Rooms 1 & 2; Studios 1-5 – Ends at 4:25pm

4:30pm - NobleCon15 adjourns


N O B L E C O N 1 4    S P O N S O R S

©2018 Noble Capital Markets, Inc. Members FINRA, SIPC, MSRB